This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome or Non-Hodgkins Lymphoma
and you are
under 19
years old
-
The phase for this study is not defined.
Show me locations

The purpose

Approximately 30% of patients who are candidates for bone marrow transplants do not have an HLA-matched, or close to matched, donor available. For this reason, doctors have been testing ways to make transplants from HLA-partially matched donors as safe and effective as transplants from HLA-matched donors. This study is being done to test the safety and the treatment results of a specific kind of transplant. In this transplant, blood from two donors will be used. Each donor will share one half of your HLA type. Blood from both donors will be transplanted at the same time.

Provided treatments

  • Radiation: total-body irradiation (TBI)
  • Drug: thiotepa
  • Drug: fludarabine phosphate
  • Drug: melphalan
  • Biological: anti-thymocyte globulin
  • Procedure: allogeneic hematopoietic stem cell transplantation
  • Biological: peripheral blood stem cell transplantation
  • Other: laboratory biomarker analysis
Tris trial is registered with FDA with number: NCT01598025. The sponsor of the trial is Memorial Sloan Kettering Cancer Center and it is looking for 3 volunteers for the current phase.
Official trial title:
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor